AR061564A1 - Derivados de isoindoles, composiciones farmaceuticas y usos - Google Patents

Derivados de isoindoles, composiciones farmaceuticas y usos

Info

Publication number
AR061564A1
AR061564A1 ARP070102733A ARP070102733A AR061564A1 AR 061564 A1 AR061564 A1 AR 061564A1 AR P070102733 A ARP070102733 A AR P070102733A AR P070102733 A ARP070102733 A AR P070102733A AR 061564 A1 AR061564 A1 AR 061564A1
Authority
AR
Argentina
Prior art keywords
alkyl
heterocyclyl
heteroaryl
nr8r9
cycloalkyl
Prior art date
Application number
ARP070102733A
Other languages
English (en)
Original Assignee
Astex Therapeutics Ltd
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38833680&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR061564(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astex Therapeutics Ltd, Astrazeneca Ab filed Critical Astex Therapeutics Ltd
Publication of AR061564A1 publication Critical patent/AR061564A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

Estos compuestos proporcionan un tratamiento o profilaxis de dificultades cognitivas, enfermedad de Alzheimer, neurodegeneracion y demencia. Reivindicacion 1: Un compuesto de formula (1) donde R1 se selecciona entre hidrogeno, nitro, ciano, -Q- alquiIo C1-6, -Q-alquenilo C2-6, -Q-alquinilo C2-6, -Q-cicloaIquilo C3-6, -Q-cicloalquenilo C5-7, -Q-alquilC1-6cicIoalquilo C3-6, -Q-arilo, -Q-heteroarilo, -Q-alquilC1-6arilo, -Q-alquilC1-6heteroarilo, -Q-heterociclilo y -Q-alquilC1-6heterociclilo, donde dicho -Q-alquiIo C1-6, -Q-alquenilo C2-6, -Q-alquinilo C2-6, -Q-cicloaIquilo C3-6, -Q-cicloalquenilo C5-7, -Q-alquilC1-6cicIoalquilo C3-6, -Q-arilo, -Q-heteroarilo, -Q-alquilC1-6arilo, -Q-alquilC1-6heteroarilo, -Q-heterociclilo o -Q-alquilC1- 6heterociclilo está opcionalmente sustituido con uno, dos o tres R7; R2 es (C(R4)(R5))nR6, alquenil C2-4R6, alquinil C2-4R6, cicloalquenil C3-7R6, nitro o ciano y si n>1 entonces cada C(R4)(R5) es independiente de los otros; R3 se selecciona de manera independiente entre hidrogeno, halogeno, alquiIo C1-6, alquenilo C3-6, alquinilo C3-6, cicloalquilo C3-6, cicloalquenilo C5-7, arilo, heteroarilo, heterociclilo, alquiIC1-6cicIoalquiIo C3-6, alquilC1-6arilo, alquiIC1-6heteroariIo y alquilC1- 6heterociclilo, donde dicho alquiIo C1-6, alquenilo C3-6, alquinilo C3-6, cicloalquilo C3-6, cicloalquenilo C5-7, arilo, heteroarilo, heterociclilo, alquiIC1-6cicIoalquiIo C3-6, alquilC1-6arilo, alquiIC1-6heteroariIo o alquilC1-6heterociclilo está opcionalmente sustituido con uno, dos o tres A; -Q- es un enlace directo, -CONH-, -CO-, -CON(alquil C1-6)-, -CON(cicloalquil C3-6)-, -SO-, -SO2-, -SO2NH-, -SO2N(alquil C1-6)-, -SO2N(cicloalquil C3-6)-, -NHSO2-, -N(alquil C1-6)SO2-, -NHCO-, -N(aIquil C1-6)CO-, -N(cicloalquil C3-6)CO- o -N(cicloalquil C3-6)SO2-; R4 y R5 se seleccionan de manera independiente entre hidrogeno., alquilo C1-6, ciano, halo o nitro; o R4 y R5 juntos forman oxo, cicloalquilo C3-6 o heterociclilo; R6 se selecciona entre metilo, cicloalquilo C3-6, heterociclilo, arilo y heteroarilo donde cada uno de dichos metilo, cicloalquilo C3-6, heterociclilo, arilo o heteroarilo está opcionalmente sustituido con entre uno y cuatro R7, y donde cualquiera de los grupos individuales arilo o heteroarilo puede estar opcionalmente fusionado con un grupo cicloalquilo, cicloalquenilo o heterociclilo de 4, 5, 6 o 7 miembros para formar un sistema anular bicíclico donde el sistema anular bicíclico está opcionalmente sustituido con entre uno y cuatro A; R7 se selecciona de manera independiente entre halogeno. nitro, CHO, alquil C0-6CN, Oalquil C1-6CN, alquil C0-6OR8, Oalquil C2-6OR8, hidroxi, fluormetilo, difluormetilo, trifluormetilo, fluormetoxi, difluormetoxi, trifluormetoxi, alquil C0-6NR8R9, Oalquil C2-6NR8R9, Oalquil C2-6Oalquil C2-6NR8R9, NR8NOR9, alquil C0-6CO2R8, Oalquil C1-6CO2R8, alquil C0-6CONR8R9, Oalquil C1-6CONR8R9, Oalquil C2-6NR8(CO)R9, alquil C0-6NR8(CO)R9, O(CO)NR8R9, NR8(CO)OR9, NR8(CO)NR8R9, O(CO)OR8, O(CO)R8, alquil C0-6COR8, Oalquil C1-6COR8, NR8(CO)(CO)R8, NR8(CO)(CO)NR8R9, alquil C0-6SR8, alquil C0-6(SO2)NR8R9, Oalquil C1-6NR8(SO2)R9, Oalquil C0-6(SO2)NR8R9, alquil C0-6(SO)NR8R9, Oalquil C1-6(SO)NR8R9, OSO2R8, SO3R8, aIquil C0-6NR8(SO2)NR8R9, alquil C0-6NR8(SO)R9, Oalquil C2-6NR8(SO)R8, Oalquil C1-6SO2R8, alquil C1-6SO2R8, alquil C0-6SOR8, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilC0-6cicIoalquiloC3-6, alquilC0-6arilo, aIquilC0- 6heteroarilo, alquilC0-6heterociclilo y OalquilC2-6heterociclilo, donde cualquier alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilC0-6cicIoalquiloC3-6, alquilC0-6arilo, aIquilC0-6heteroarilo, alquilC0-6heterociclilo u OalquilC2-6heterociclilo está opcionalmente sustituido con uno o más R14, y donde cualquiera de los grupos individuales arilo o heteroarilo puede estar opcionalmente fusionado con un grupo cicloalquilo, cicloalquenilo o heterociclilo de 4, 5, 6 o 7 miembros para formar un sistema anular bicíclico donde el sistema anular bicíclico está opcionalmente sustituido con entre uno y cuatro A; con la condicion de que dicho sistema anular bicíclico no es un sistema anular indano, benzo[1,3]dioxol o 2,3-dihidrobenzo[1,4]- dioxina; R14 se selecciona entre halogeno, nitro, CHO, alquiI C0-6CN, Oalquil C1-6CN, alquil C0-6OR8, Oalquil C1-6OR8, fluormetilo, difluormetilo, trifluormetilo, fluormetoxi, difluormetoxi, trifluormetoxi, alquil C0-6NR8R9, Oalquil C2-6NR8R9, Oalquil C2-6Oalquil C2-6NR8R9, NR8OR9, alquil C0-6CO2R8, Oalquil C1-6CO2R6, aIquil C0-6CONR8R9, OaIquiI C1-6CONR8R9, Oalquil C2-6NR8(CO)R9, alquil C0-6NR8(CO)R9, O(CO)NR8R9, NR8(CO)OR9, NR8(CO)NR8R9, O(CO)OR8, O(CO)R8, alquil C0-6COR8, Oalquil C1- 6COR8, NR8(CO)(CO)R8, NR8(CO)(CO)NR8R9, alquil C0-6SR8, alquil C0-6(SO2)NR8R9, Oalquil C2-6NR8(SO2)R9, Oalquil C0-6(SO2)NR8R9, alquil C0-6(SO)NR8R9, Oalquil C1-6(SO)NR8R9, OSO2R8, SO3R8, alquil C0-6NR8(SO2)NR8R9, aIquil C0-6NR8(SO)R9, Oalquil C2- 6NR8(SO)R8, Oalquil C1-6SO2R8, alquil C0-6SO2R8, alquil C0-6SOR8, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilC0-6cicloalquiloC3-6, alquilC0-6arilo, alquilC0-6heteroarilo, alquilC0-6heterociclilo y OalquilC2-6heterociclilo donde cualquier alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilC0-6cicloalquiloC3-6, alquilC0-6arilo, alquilC0-6heteroarilo, alquilC0-6heterociclilo u OalquilC2-6heterociclilo está opcionalmente sustituido con entre uno y cuatro A; R8 y R9 se seleccionan de manera independiente entre hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, fluormetilo, difluormetilo, trifluormetilo, fluormetoxi, difluormetoxi, trifluormetoxi, alquilC0-6cicloalquiloC3-6, alquilC0-6arilo, alquilC0-6heleroarilo, alquilC0- 6heterociclilo y alquiIC1-6NR10R11 donde dicho alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilC0-6cicloalquiloC3-6, alquilC0-6arilo, alquilC0-6heteroarilo o alquilC0-6heterociclilo está opcionalmente sustituido con A; o R8 y R9 pueden formar juntos un anillo heterocíclico de 4 a 6 miembros que contiene uno o más heteroátomos seleccionados entre N, O o S que está opcionalmente sustituido con A; cada vez que dos grupos R8 aparecen en la estructura entonces opcionalmente pueden formar juntos un anillo heterocíclico de 5 o 6 miembros que contiene uno o más heteroátomos seleccionados entre N, O o S, que está opcionalmente sustituido con A; R10 y R11 se seleccionan de manera independiente entre hidrogeno, alquilo C1-6, alquenilo C3- 6, alquinilo C3-6, alquilC0-6cicloalquiloC3-6, alquilC0-6arilo, alquilC0-6heterociclilo y alquilC0-6heteroarilo, donde dicho alquilo C1-6, alquenilo C3-6, alquinilo C3-6, alquilC0-6cicloalquiloC3-6, alquilC0-6arilo, alquilC0-6heterociclilo o alquilC0-6heteroarilo está opcionalmente sustituido con A; o R10 y R11 pueden formar juntos un anillo heterocíclico de 4 a 6 miembros que contiene uno o más heteroátomos seleccionados entre N, O o S opcionalmente sustituido con A; m es 0, 1, 2 o 3; n es 0, 1, 2 o 3; A se selecciona de manera independiente entre oxo, halogeno, nitro, CN, OR12, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilC0-6arilo, alquilC0-6heteroarilo, alquilC0-6cicloalquiloC3-6, alquilC0-6heterociclilo, fluormetilo, difluormetilo, trifluormetilo, fluormetoxi, difluormetoxi, trifluormetoxi, Oalquil C2-6NR12R13, NR2R13, CONR12R13, NR12(CO)R13, O(CO)alquilo C1-6, (CO)Oalquilo C1-6, COR12, (SO2)NR12R13, NSO2R12, SO2R12, SOR12, (CO)alquil C1-6NR12R13, (SO2)alquil C1- 6NR12R13, OSO2R12 y SO3R12, donde dicho alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilC0-6arilo, alquilC0-6heteroarilo, alquilC0-6heterociclilo o alquilC0-6cicloalquiloC3-6 está opcionalmente sustituido con halo, OSO2R12, SO3R12, nitro, ciano, OR12, alquilo C1-6, fluormetilo, difluormetilo, trifluormetilo, fluormetoxi, difluormetoxi o trifluormetoxi; R12 y R13 se seleccionan de manera independiente entre hidrogeno, alquilo C1-6, cicloalquilo C3-6, arilo, heteroarilo y heterociclilo, donde dicho alquilo C1-6, cicloalquilo C3-6, arilo, heteroarilo o heterociclilo está opcionalmente sustituido con uno, dos o tres hidroxi, ciano, halo o alquiloxi C1-3, o R12 y R13 pueden formar juntos un anillo heterocíclico de 4 a 6 miembros que contiene uno o más heteroátomos seleccionados entre N, O o S opcionalmente sustituido con hidroxi, alquiloxi C1-3, ciano o halo; con la condicion de que se excluyan los siguientes compuestos: 3-amino-1-ciano-N-fenil-1H-isoindol-1 - carboxamida; 3- amino-1-(1H-bencimidazol-2-il)-1H-isoindol-1-carbonitrilo; 4,4'-(3-amino-1H-isoindol-1,1-diiI)difenol; 1-fenil-1H-isoindol-3-amina; 1-metil-1 H-isoindol-3-amina, 1,1-dimetil-1H-isoindol-3-amina; 2-[3-amino-1-(4-hidroxifenil)-1H- isoindol-1-il]fenol; como una base libre o una sal, solvato o solvato de una sal farmacéuticamente aceptable del mismo.
ARP070102733A 2006-06-22 2007-06-21 Derivados de isoindoles, composiciones farmaceuticas y usos AR061564A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81580006P 2006-06-22 2006-06-22
US81855706P 2006-07-05 2006-07-05
US89124207P 2007-02-23 2007-02-23

Publications (1)

Publication Number Publication Date
AR061564A1 true AR061564A1 (es) 2008-09-03

Family

ID=38833680

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102733A AR061564A1 (es) 2006-06-22 2007-06-21 Derivados de isoindoles, composiciones farmaceuticas y usos

Country Status (17)

Country Link
US (2) US7855213B2 (es)
EP (1) EP2035378A4 (es)
JP (1) JP2009541311A (es)
KR (1) KR20090031585A (es)
AR (1) AR061564A1 (es)
AU (1) AU2007261749B2 (es)
CA (1) CA2656625A1 (es)
CL (1) CL2007001830A1 (es)
EC (1) ECSP088972A (es)
IL (1) IL195670A0 (es)
MX (1) MX2008015719A (es)
MY (1) MY147390A (es)
NO (1) NO20090246L (es)
NZ (1) NZ574262A (es)
TW (1) TW200815349A (es)
UY (1) UY30426A1 (es)
WO (1) WO2007149033A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2006014944A1 (en) 2004-07-28 2006-02-09 Schering Corporation Macrocyclic beta-secretase inhibitors
KR20080028881A (ko) 2005-06-14 2008-04-02 쉐링 코포레이션 헤테로사이클릭 아스파르틸 프로테아제 억제제, 이의제조방법 및 용도
TWI332005B (en) 2005-06-14 2010-10-21 Schering Corp Aspartyl protease inhibitors
EP2032542A2 (en) 2006-06-12 2009-03-11 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW200815349A (en) * 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
WO2009005470A1 (en) * 2007-07-05 2009-01-08 Astrazeneca Ab Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
WO2009005471A1 (en) * 2007-07-05 2009-01-08 Astrazeneca Ab Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
TW200948364A (en) 2008-04-22 2009-12-01 Schering Corp Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
BRPI0918449A2 (pt) 2008-09-11 2019-09-24 Amgen Inc compostos de anel espiro-tricíclico como moduladores de beta-secretas e métodos de uso
EP2367826A4 (en) * 2008-11-06 2012-07-04 Astrazeneca Ab MODULATORS OF THE PROTEIN -AMYLOID
TW201020244A (en) * 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
WO2010056194A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab 5h-pyrrolo [ 3, 4-b] pyridin derivatives and their use
WO2010056195A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 575
WO2011002409A1 (en) * 2009-07-02 2011-01-06 Astrazeneca Ab 5h-pyrrolo[3,4-£>]pyrazin-7-amine derivatives inhibitors of beta-secretase
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
US8557826B2 (en) 2009-10-08 2013-10-15 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2011044185A2 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
AU2011227511B2 (en) 2010-03-15 2014-02-20 Amgen Inc. Spiro-tetracyclic ring compounds as Beta - secretase modulators
JP5584352B2 (ja) 2010-03-15 2014-09-03 アムジエン・インコーポレーテツド β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途
WO2011142716A1 (en) * 2010-05-12 2011-11-17 Astrazeneca Ab Novel hemifumarate salt of isoindole compound acting as bace inhibitor
EP2601197B1 (en) 2010-08-05 2014-06-25 Amgen Inc. Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
JP2013542973A (ja) 2010-11-22 2013-11-28 ノスシラ、ソシエダッド、アノニマ 神経変性疾患または神経変性状態を治療するためのビピリジンスルホンアミド誘導体
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2747769B1 (en) 2011-08-22 2017-08-02 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2013142370A1 (en) 2012-03-19 2013-09-26 Varghese John APP SPECIFIC BACE INHIBITORS (ASBIs) AND USES THEREOF
US9416129B2 (en) 2012-10-17 2016-08-16 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use
WO2014062549A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US10202355B2 (en) 2013-02-12 2019-02-12 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
ATE198622T1 (de) 1993-10-27 2001-01-15 Elan Pharm Inc Transgene tiere, die app allele mit der schwedischen mutation beherbergen
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
DE4419849A1 (de) 1994-06-07 1995-12-14 Hoechst Ag Isoindolinpigmente
PL181895B1 (pl) 1994-06-16 2001-10-31 Pfizer Nowe pirazolo-i pirolopirydyny _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ PL PL PL PL
DE19516804A1 (de) 1995-05-08 1996-11-14 Hoechst Ag Isoindolinpigmente auf Basis von Aminochinoxalindionen
EP0871720A2 (en) 1995-06-07 1998-10-21 Athena Neurosciences, Inc. Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
US5744346A (en) * 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
US6211235B1 (en) 1996-11-22 2001-04-03 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
EP1012151B1 (en) 1997-09-02 2002-08-07 Bristol-Myers Squibb Pharma Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
US5981168A (en) 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
CN1502692A (zh) 1998-09-24 2004-06-09 �������Ŷ���Լ��������˾ 阿尔茨海默氏疾病分泌酶
US6245884B1 (en) 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US6313268B1 (en) * 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
EP1165609A2 (en) 1999-02-10 2002-01-02 Elan Pharmaceuticals, Inc. Human beta-secretase enzyme, inhibitors and their compositions and uses
WO2000058479A1 (en) 1999-03-26 2000-10-05 Amgen Inc. Beta secretase genes and polypeptides
US6376530B1 (en) * 1999-05-10 2002-04-23 Merck & Co., Inc. Cyclic amidines useful as NMDA NR2B antagonists
EP1192177A1 (en) 1999-06-15 2002-04-03 Elan Pharmaceuticals, Inc. Statine-derived tetrapeptide inhibitors of beta-secretase
CN1379819A (zh) 1999-06-28 2002-11-13 俄克拉荷马州医学研究基金会 具有催化活性的重组memapsin蛋白酶及其应用方法
ATE431419T1 (de) 1999-09-23 2009-05-15 Pharmacia & Upjohn Co Llc Alzheimer krankheit sekretase, app (amyloid vorlaüfer-protein) substrate dafür und verwendungen
GB9924957D0 (en) 1999-10-21 1999-12-22 Smithkline Beecham Plc Novel treatment
ES2248356T3 (es) 2000-06-30 2006-03-16 Elan Pharmaceuticals, Inc. Compuestos para tratar la enfermedad de alzheimer.
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
AU2001281250A1 (en) 2000-08-11 2002-02-25 The Brigham And Women's Hospital, Inc. (hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production
ATE355520T1 (de) 2000-09-22 2006-03-15 Wyeth Corp Kristallstruktur von bace und verwendungen dafür
JP2004149429A (ja) * 2002-10-29 2004-05-27 Takeda Chem Ind Ltd インドール化合物およびその用途
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
PL1699455T3 (pl) 2003-12-15 2013-10-31 Merck Sharp & Dohme Heterocykliczne inhibitory proteaz aspartylowych
WO2005097767A1 (en) 2004-03-30 2005-10-20 Merck & Co., Inc. 2-aminothiazole compounds useful as aspartyl protease inhibitors
WO2005112921A2 (en) * 2004-04-26 2005-12-01 Vanderbilt University Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
US20080153869A1 (en) 2004-06-14 2008-06-26 Bressi Jerome C Kinase Inhibitors
AU2005264917A1 (en) 2004-06-16 2006-01-26 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of B-secretase
PE20060459A1 (es) 2004-06-16 2006-05-30 Wyeth Corp DERIVADOS DE AMINO-5,5-DIFENILIMIDAZOLONA COMO INHIBIDORES DE LA ß-SECRETASA
JPWO2006006520A1 (ja) 2004-07-09 2008-04-24 株式会社ジェノファンクション 新規創薬標的の探索方法
US7732038B2 (en) 2004-07-12 2010-06-08 Dai Nippon Printing Co., Ltd. Electromagnetic wave shielding filter
PT1789398E (pt) * 2004-08-06 2010-10-21 Janssen Pharmaceutica Nv Derivados de 2-amino- quinazolina úteis como inibidores de β-secretase (bace)
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
EA200700712A1 (ru) 2004-09-21 2008-02-28 Эсерсис, Инк. Производные индолуксусной кислоты, способ получения таких производных (варианты), фармацевтическая композиция, набор на их основе, способ ингибирования связывания эндогенных лигандов и способ лечения заболеваний и расстройств, восприимчивых к ингибированию связывания эндогенных лигандов с рецептором crth-2
US20090221579A1 (en) 2004-10-15 2009-09-03 Jeffrey Scott Albert Substituted Amino-Compounds and Uses Thereof
US20090062282A1 (en) 2004-10-15 2009-03-05 Astrazeneca Ab Substituted Amino-Pyrimidones and Uses Thereof
EP1831170A4 (en) 2004-12-14 2009-10-14 Astrazeneca Ab SUBSTITUTED AMINOPYRIDINES AND THEIR USE
CN101103034A (zh) 2005-01-14 2008-01-09 惠氏公司 抑制β-分泌酶的氨基-咪唑酮
NZ561029A (en) 2005-03-14 2011-03-31 High Point Pharmaceuticals Llc Benzazole dervatives, compositions, and method of use as beta-secretase inhibitors
KR20080028881A (ko) 2005-06-14 2008-04-02 쉐링 코포레이션 헤테로사이클릭 아스파르틸 프로테아제 억제제, 이의제조방법 및 용도
MX2007016185A (es) 2005-06-14 2008-03-07 Schering Corp Inhibidores de aspartil proteasa heterociclicos macrociclicos.
WO2006138217A1 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
WO2006138230A2 (en) 2005-06-14 2006-12-28 Schering Corporation The preparation and use of protease inhibitors
TWI332005B (en) 2005-06-14 2010-10-21 Schering Corp Aspartyl protease inhibitors
EP1896430B1 (en) 2005-06-14 2010-11-24 Schering Corporation The preparation and use of compounds as aspartyl protease inhibitors
WO2007005404A1 (en) 2005-06-30 2007-01-11 Wyeth AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
WO2007011833A2 (en) 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
US7601751B2 (en) 2005-09-01 2009-10-13 Bristol-Myers Squibb Company Indole acetic acid acyl guanidines as β-secretase inhibitors
ES2476027T3 (es) * 2005-10-25 2014-07-11 Shionogi & Co., Ltd. Derivados de aminodihidrotriazina
ATE478070T1 (de) 2005-10-27 2010-09-15 Schering Corp Heterozyklische aspartyl-proteasehemmer
US7560451B2 (en) 2005-10-31 2009-07-14 Schering Corporation Aspartyl protease inhibitors
US20080255167A1 (en) 2005-11-15 2008-10-16 Jeffrey Albert Novel 2-Aminopyrimidine or 2-Aminiopyridinone Derivatives and Their Use
TW200804290A (en) 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
JP2009515951A (ja) 2005-11-15 2009-04-16 アストラゼネカ・アクチエボラーグ 新規な２−アミノピリミジノンまたは２−アミノピリジノン誘導体およびそれらの使用
EP1951680A4 (en) 2005-11-15 2011-08-10 Astrazeneca Ab NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
US20090176850A1 (en) 2005-11-21 2009-07-09 Astrazeneca Ab Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia
AR058381A1 (es) 2005-12-19 2008-01-30 Astrazeneca Ab Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica
WO2007114771A1 (en) 2006-04-05 2007-10-11 Astrazeneca Ab 2-AMINOPYRIMIDIN-4-ONES AND THEIR USE FOR TREATING OR PREVENTING Aβ-RELATED PATHOLOGIES
TW200808751A (en) 2006-04-13 2008-02-16 Astrazeneca Ab New compounds
EP2032542A2 (en) 2006-06-12 2009-03-11 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW200815449A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds II
TW200815443A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds I
TW200815447A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
TW200808796A (en) 2006-06-14 2008-02-16 Astrazeneca Ab New compounds III
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
WO2008063114A1 (en) 2006-11-20 2008-05-29 Astrazeneca Ab Amino- imidazolones and their use as medicament for treating cognitive impairment alzheimer disease, neurodegeneration and dementia
TW200831484A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
TW200831091A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
WO2008076043A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5,5-diaryl-imidazol-4-ones
TW200902503A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
WO2009005470A1 (en) 2007-07-05 2009-01-08 Astrazeneca Ab Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
WO2009005471A1 (en) 2007-07-05 2009-01-08 Astrazeneca Ab Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
WO2010056195A1 (en) 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 575
TW201020244A (en) * 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
WO2010056194A1 (en) 2008-11-14 2010-05-20 Astrazeneca Ab 5h-pyrrolo [ 3, 4-b] pyridin derivatives and their use

Also Published As

Publication number Publication date
MY147390A (en) 2012-11-30
AU2007261749B2 (en) 2011-11-03
UY30426A1 (es) 2008-01-31
MX2008015719A (es) 2009-01-09
IL195670A0 (en) 2009-09-01
EP2035378A4 (en) 2012-01-25
CA2656625A1 (en) 2007-12-27
JP2009541311A (ja) 2009-11-26
NZ574262A (en) 2011-11-25
KR20090031585A (ko) 2009-03-26
EP2035378A1 (en) 2009-03-18
AU2007261749A1 (en) 2007-12-27
US7855213B2 (en) 2010-12-21
CL2007001830A1 (es) 2008-04-04
US20110059992A1 (en) 2011-03-10
ECSP088972A (es) 2009-01-30
NO20090246L (no) 2009-03-20
TW200815349A (en) 2008-04-01
WO2007149033A1 (en) 2007-12-27
US20080171771A1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
AR061564A1 (es) Derivados de isoindoles, composiciones farmaceuticas y usos
AR058381A1 (es) Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica
AR057984A1 (es) DERIVADOS DE IMIDAZOL INHIBIDORES DE LA PROTEINA beta AMILOIDE
AR061372A1 (es) Amino-imidazoles y sus usos como medicamentos para el tratamiento de mal de alzheimer, demencia y neurodegeneracion
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
AR061371A1 (es) Amino - imidazolonas y su uso como medicamento para la enfermedad de alzheimer y otras enfermedades neurodegenerativas.
AR066562A1 (es) Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR065322A1 (es) 2-aminooxazolinas comoligandos de taar1
AR036716A1 (es) Un compuesto derivado de bencimidazolidinona, metodos que lo utilizan, una composicion farmaceutica que lo comprende y uso de dicho compuesto o composicion
AR043434A1 (es) Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos
AR066561A1 (es) Derivados de imidazol, composiciones farmaceuticas y usos
AR079553A1 (es) Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros.
AR061370A1 (es) Derivados de imidazopirimidina
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR066111A1 (es) Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto
AR074966A1 (es) Compuestos amino-heterociclicos
AR058073A1 (es) Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
AR076551A1 (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituida, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por dppi
AR049696A1 (es) Derivados de indol
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR070463A1 (es) Compuestos de amina y eter que modulan el receptor cb2
AR057989A1 (es) Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas
AR067662A1 (es) Derivados de benzo[d]isoxazol-3-il-piperidina, medicamentos que los contienen y usos terapeuticos para enfermedades asociadas al sistema nervioso.
AR060287A1 (es) Compuesto de 5,6 dihidro-3h-pirrolo[1,2,3-de]quinoxalini-3-ona, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuesto intermediario util para su preparacion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal